Last reviewed 2026-04-23 · How we verify

Maternal zidovudine/lamivudine/lopinavir-ritonavir

Maternal zidovudine/lamivudine/lopinavir-ritonavir is a Antiretroviral combination therapy (NRTI + protease inhibitor) Small molecule drug developed by Centers for Disease Control and Prevention. It is currently in Phase 3 development for Prevention of mother-to-child HIV transmission in pregnant women, HIV infection in pregnancy. Also known as: Combivir tabs (zidovudine 300mg and lamivudine 150mg), Aluvia tabs (lopinavir 200mg /ritonavir 50mg).

This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission.

This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission. Used for Prevention of mother-to-child HIV transmission in pregnant women, HIV infection in pregnancy.

At a glance

Mechanism of action

Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while lopinavir-ritonavir is a protease inhibitor combination that blocks HIV protease. Together, they suppress HIV replication in maternal circulation and reduce the viral load transmitted to the fetus during pregnancy and delivery.

Approved indications

• Prevention of mother-to-child HIV transmission in pregnant women
• HIV infection in pregnancy

Common side effects

• Nausea
• Diarrhea
• Lipodystrophy
• Hepatotoxicity
• Pancreatitis
• Lactic acidosis

Key clinical trials

• IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
• Antiretroviral Regime for Viral Eradication in Newborns (PHASE4)
• Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PHASE3)
• Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (PHASE2)
• Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (PHASE3)
• Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV (PHASE2)
• Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV (PHASE3)
• Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Maternal zidovudine/lamivudine/lopinavir-ritonavir CI brief — competitive landscape report
• Maternal zidovudine/lamivudine/lopinavir-ritonavir updates RSS · CI watch RSS
• Centers for Disease Control and Prevention portfolio CI

Frequently asked questions about Maternal zidovudine/lamivudine/lopinavir-ritonavir

Related

• Drug class: All Antiretroviral combination therapy (NRTI + protease inhibitor) drugs
• Target: All drugs targeting HIV reverse transcriptase, HIV protease
• Manufacturer: Centers for Disease Control and Prevention — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for Prevention of mother-to-child HIV transmission in pregnant women
• Indication: Drugs for HIV infection in pregnancy
• Also known as: Combivir tabs (zidovudine 300mg and lamivudine 150mg), Aluvia tabs (lopinavir 200mg /ritonavir 50mg)
• Compare: Maternal zidovudine/lamivudine/lopinavir-ritonavir vs similar drugs
• Pricing: Maternal zidovudine/lamivudine/lopinavir-ritonavir cost, discount & access